Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have found that pembrolizumab, an immunotherapy drug, can effectively treat malignant pleural mesothelioma, a disease primarily caused by asbestos inhalation. The study, led by Evan Alley, showed promising results with tumor reduction and improved overall survival in patients.
Researchers developed a new method to search for synthetic-lethal gene combinations using CRISPR/Cas9, uncovering 120 new opportunities for cancer drug development. The technique allowed them to test thousands of gene mutation combinations simultaneously, revealing more than 120 new synthetic-lethal interactions.
A new study by Penn researchers found that Medicare patients with chronic illnesses, such as cancer and rheumatoid arthritis, paid an average of $6,322 per year in out-of-pocket costs under Medicare Part D. The study proposes policy changes to cap annual out-of-pocket costs and spread them more evenly throughout the year.
The absence of protein SPRED2 alone can trigger excessive grooming behavior in mouse models. The study identifies the Ras/ERK-MAP kinase cascade as a key signaling pathway involved in obsessive-compulsive disorder (OCD). Administering an inhibitor to this pathway improves OCD symptoms, suggesting new potential treatments.
Researchers at the University of Bradford have developed a peptide that blocks RAN protein and kill cancer cells. The new treatment uses nanoparticles to deliver the peptide directly into cancer cells, showing promising results in lab tests.
Researchers developed a new drug delivery method using antibody-drug conjugates (ADCs) that show high precision and stability. The method successfully treated hard-to-treat solid and liquid tumors, including HER2 breast cancer and CD138 multiple myeloma, without harming healthy cells.
The ABC Global Alliance, led by ESO, has launched a call-to-action to improve and extend the lives of patients with advanced breast cancer by 2025. The initiative outlines key gaps and actionable imperatives across patient care, societal support, and scientific investment for mBC.
Three Harvard experts discuss the economics of precision medicine, highlighting factors such as innovative incentives, higher prices due to biologic drugs, and limited competition. The authors propose potential solutions to increase patient access to these medicines, including financial instruments and price competition.
Researchers develop CelePlum-777, a nanoparticle-based drug combo that kills melanoma cells with minimal side effects. The treatment reduces cancer cell growth and resists resistance development, offering new hope for melanoma patients.
A University of Leicester study found that folinic acid can protect neurons in fruit flies with Parkinson's disease, offering potential hope for people with early-onset forms of the condition. The researchers believe that supplementing folinic acid could be a faster and more effective treatment option than developing new drugs.
A phase 2 clinical trial of sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2, achieved a response in 21 participants with advanced triple-negative breast cancer. The responses were early and durable, lasting up to 20 months, with improved overall survival.
Researchers discovered that many breast cancer patients have mutational signatures similar to those with faulty BRCA1 or BRCA2 genes, suggesting they may also benefit from existing PARP inhibitor treatments. This opens up the possibility of treating up to 20% of women with these drugs.
Scientists have designed two new drug candidates that target specific types of cancer by binding to defective RNAs. The compounds, called Targapremir-18a and Targapremir-210, successfully kill prostate and triple negative breast cancer cells without causing broader side effects.
Recent advances in understanding regulatory mechanisms of HH pathway and chemical regulation are discussed. CAS scientists propose a hypothetical model for endogenous chemical modulation and suggest precise interventions for better therapeutic outcomes.
Researchers at Mayo Clinic have identified a specific protein implicated in drug resistance, as well as a possible therapeutic tool. By engineering a peptide that blocks the activity of another protein ERK, the team found that it can prevent chemotherapy resistance and tumor growth.
Researchers have identified a class of enzymes that play an active role in regulating stress granules, which help cancer cells defend themselves against treatments. Disabling these enzymes can lower SG levels, opening doors to new therapeutics for various diseases.
A new study shows that even with PD-1 blockade, tumor-specific T cells require CD28 co-stimulation to expand and restore effective immune responses. This finding suggests that only a subset of tumor-specific CD8 T cells will proliferate after PD-1-directed therapy.
A nearly 11-year follow-up study published in the New England Journal of Medicine shows an estimated overall survival rate of 83.3% among 1,106 patients with chronic myeloid leukemia treated with Gleevec. The treatment has been proven effective against multiple forms of cancer, including pediatric CML and gastrointestinal stromal tumor.
Researchers at Scripps Research Institute have discovered a disordered protein, CITED2, that outcompetes another protein, HIF1α, for cellular binding targets. This finding has implications for future cancer drugs, suggesting a more efficient approach to interrupting cancer cell survival mode.
Cabozantinib activates neutrophils, the first-responders of the immune system, to infiltrate tumor cells and trigger an immune response that leads to complete clearance of invasive prostate cancers. This innovative approach could lead to novel combination cancer immunotherapies.
Researchers at UCI have identified a specific mutation that allows melanoma tumor cells to evade the immune system. This finding may lead to more effective immunotherapies and targeted treatments for patients with melanoma.
Researchers have identified a protein biomarker, CD151, expressed on tumour cells of high-grade serous ovarian cancer, which is linked to poor prognosis. The study provides new information about possible targets for ovarian cancer treatment and has the potential to develop a clinical screening tool.
Researchers in Florida have identified a possible association between cancer incidence rates and Superfund sites. The study found that counties with Superfund sites had a 6% higher rate of adult cancer cases, suggesting a link between toxic environmental waste and adverse health outcomes.
A study found that the drug everolimus protects ovaries from cyclophosphamide, a common chemotherapy used against breast cancer, which depletes egg cells needed to achieve pregnancy. Female mice treated with everolimus and chemotherapy had more than twice as many offspring as those treated with chemotherapy alone.
A recent study published in JAMA Oncology found that exercise alone and psychological interventions significantly reduced cancer-related fatigue. The research analyzed 113 studies involving over 11,000 patients and concluded that exercise is the most effective approach to alleviate this debilitating side effect of cancer treatment.
A meta-analysis of 113 randomized clinical trials found that exercise, psychological interventions, and their combination were effective in reducing cancer fatigue. Pharmaceutical interventions did not show the same magnitude of improvement.
Researchers at Beth Israel Deaconess Medical Center have discovered a vulnerability in triple-negative breast cancer cells that can be exploited by blocking pyrimidine production. This finding provides a new strategy to combat the disease, which currently has limited treatment options.
Researchers at Ohio State University Comprehensive Cancer Center have identified a mechanism by which cancer cells develop resistance to FGFR inhibitors. By inhibiting the regulatory protein Akt, they found that cell proliferation, migration, and invasion could be slowed in lung and bladder cancer cells.
A rheumatoid arthritis drug has been found to block a metabolic pathway that drives tumor growth in aggressive cancers with the PTEN gene mutation. Leflunomide kills human breast cancer cells in mice by damaging DNA produced through the pathway.
Breast cancer patients who receive nine-week Herceptin treatment experience significant increases in survival rates and quality-adjusted life-years. The study found that switching to the nine-week course could save the NHS over £100 million a year, while being just as effective as the current 12-month duration.
A new potential strategy has been discovered to personalize therapy for brain and blood cancers, targeting tumors lacking the protein PTEN. The approach combines two pharmaceutical-grade drugs to eliminate PTEN-deficient cancer cells, offering a promising new treatment option.
Researchers have identified a powerful new pathway for enhanced blood cancer therapies by combining epigenetic drugs with immune-based treatments. This approach has shown promising results in inducing cancer cell death and overcoming resistance.
Researchers at MIT have developed a machine that can rapidly produce large quantities of customized peptides in about 37 seconds. This technology could help researchers generate new peptide drugs to test on various diseases and also produces customized cancer vaccines for individual patients.
A combination of two cancer drugs has been found to inhibit both dengue and Ebola virus infections in mice, with efficacy also shown against West Nile and Zika viruses. The study identified a molecular mechanism by which the drugs disrupt RNA viruses' genetic material.
A new compound developed by the Deshaies group inhibits Rpn11 activity, causing massive accumulation of dysfunctional proteins in cancer cells. This leads to catastrophic stress and cell death, making it a promising alternative to existing cancer drugs.
The Detroit Research on Cancer Survivors (Detroit ROCS) study aims to better understand the major factors affecting cancer progression, recurrence, mortality and quality of life in African American cancer survivors. The five-year, $9 million study will include 5,560 cancer survivors to identify key risk factors and develop intervention...
Researchers at Michigan State University have shown that breast cancer treatment options can be predicted based on gene expression patterns. The study identified a three-drug combination effective in stopping triple-negative breast cancer growth and suggests a personalized approach to care.
Researchers at the University of Pittsburgh School of Medicine have identified a novel genetic mechanism and marker that may predict response to a class of drugs in many cancer types. Elevated levels of IGF2BP3 protein were found in both thyroid and other common cancers, suggesting its potential as a biomarker for treatment response.
A new study found that cancer survivors are changing their prescription drug use due to financial constraints, with a significant proportion of non-elderly adults skipping medication or seeking cheaper options. This phenomenon has important policy implications and highlights the need for improved doctor-patient communication about the ...
Research from the SWOG study shows that nearly one in four patients treated with Gleevec will survive 10 years, highlighting the importance of banked biospecimens to drive new scientific findings. The study also found significant survival rates for patients with specific KIT mutations.
Researchers at Cincinnati Children's Hospital Medical Center successfully treated patients with deadly, treatment-resistant blood cancers using gene-guided therapy. The targeted approach identified specific genes fueling the diseases and prescribed molecular drugs to put them into remission.
Researchers at the Children's Hospital of Eastern Ontario discovered a combination therapy amplifies kill rates of cancer tumour cells using SMAC Mimetics and immune checkpoint inhibitors. The treatment also promotes long-term immunity against glioblastoma tumours, showing high cure rates in mice.
Researchers developed a new tool to analyze genetic changes in ovarian cancer, revealing pathways disrupted by the loss and gain of genes. The study found that targeting autophagy genes showed promise in treating chemotherapy-resistant disease.
A randomized Phase II clinical trial demonstrated that ProLon targets the aging process, reducing risk factors for age-related diseases such as diabetes, cancer, and cardiovascular disease in humans. The study found significant reductions in body weight, BMI, total body fat, and inflammation, while increasing relative lean body mass.
A UMass Amherst study found that current incentives for developing orphan drugs are not sufficient to meet patients' needs, leading to unmet health needs and barriers to access. The researchers call for a comprehensive understanding of the ethical considerations of access to safe and effective orphan drugs.
A team of experts has developed a set of diagnostic criteria for idiopathic multicentric Castleman disease, a life-threatening condition often misdiagnosed as other illnesses. The new criteria will help doctors diagnose the disease more accurately, leading to timely treatment and improved patient outcomes.
Researchers at the University of British Columbia have developed a magnetic drug implant that can deliver precise doses of medication on demand. The device uses a magnet to trigger the release of drugs into surrounding tissue, offering a potential alternative to traditional pill or injection-based treatments.
Scientists at Scripps Research Institute have been awarded $3.3 million to create a new class of anti-cancer drugs called antibody-drug conjugates (ADCs). These ADCs target aggressive breast cancer types with high efficiency.
A registry study of over 72,000 styrene-exposed employees found no increased incidence of common cancers such as oesophagus or lung cancer. However, a possible increased risk of myeloid leukaemia and nasal cancer was detected, highlighting the need for further investigation.
Sandra Horning, a cancer survivor and renowned oncologist, will receive the Duane Roth Memorial Award for her pioneering work in developing new treatments for lymphoma. Her commitment to personalized therapies and holistic approaches to patient care has improved cancer treatment outcomes.
A new UTSA study has found a potential link between a medication used to prevent infections in cancer patients and the regeneration of sperm from stem cells. Researchers discovered that G-CSF, a drug commonly used to recover from chemotherapy and radiation treatments, can also help restore male fertility.
A study found that taking abiraterone acetate, a widely used prostate cancer drug, with a low-fat breakfast is as effective as taking it on an empty stomach, but at a significantly lower cost. The finding could save patients thousands of dollars per month.
A breakthrough trial at the University of Minnesota found that a new UMN-developed drug, eBAT, significantly improved the six-month survival rate for dogs with hemangiosarcoma (HSA) to approximately 70%. The study's results suggest potential for translation into human clinical trials.
Researchers found a previously unappreciated role for Abraxane in tumor immunology, suggesting ways to improve the drug and develop new combination treatments. Nab-paclitaxel enables macrophages to switch from immune-suppressing M2 cells back into M1 cells that amplify the body's effort to kill cancer cells.
Researchers created functional microtissue technology that mimics human drug responses, identifying effective anti-cancer drugs. The vascularized micro-tumor platform accurately targets both tumor cells and vessels, offering a breakthrough in cancer treatment
A new study reveals that short fragments of circular DNA encoding cancer genes are common in cancer cells and contribute to their diversity. The research suggests that tumors with these genes on circular DNA are more resistant to treatments, making them harder to treat.
Researchers propose that aspirin's anti-tumor effect is due to its ability to block platelet interaction with cancer cells. The study suggests that aspirin can curb tumor growth by reducing circulating platelets and their activity.
In a groundbreaking study, 16 patients with severe aplastic anemia were successfully treated using partially matched bone marrow transplants followed by chemotherapy. After stopping immunosuppressive drugs over a year after their transplants, all patients showed no evidence of the disease.
Scientists have identified a distinct cell population in tumours that inhibits the body's immune response to fight cancer. By targeting these cells, researchers hope to enhance the immune system's ability to attack cancer cells.
Thomas Gajewski, a pioneer in cancer immunotherapy, has received a $4.2 million grant to support his research on overcoming tumor resistance. His team is exploring new approaches, including drugs that enhance immune system function and the role of gut microbiota in cancer.